Neutrophil to Lymphocyte Ratio in Patients With a First Episode of Psychosis: A Two-Year Longitudinal Follow-up Study
Por:
Bioque, M, Matias-Martins, AC, Llorca-Bofi, V, Mezquida, G, Cuesta, MJ, Vieta, E, Amoretti, S, Lobo, A, Gonzalez-Pinto, A, Moreno, C, Roldan, A, Martinez-Aran, A, Baeza, I, Berge, D, Garcia-Rizo, C, Herrero, SM, Bernardo, M
Publicada:
18 nov 2022
Ahead of Print:
1 jul 2022
Resumen:
Background and Hypothesis A pro-inflammatory phenotype has been related to psychotic disorders. The neutrophil-lymphocyte ratio (NLR) is an accessible biomarker that could be helpful to characterize this systemic inflammation state. Study Design This study evaluated the NLR in a cohort of 310 subjects with a first episode of psychosis (FEP) and a matched group of 215 healthy controls, recruited in 16 Spanish centers participating in the PEPs Project. We investigated the NLR measures over 2 years in a prospective, naturalistic study. Study Results At baseline, the FEP group showed a significant higher mean NLR compared to the control group (1.96 +/- 1.11 vs 1.72 +/- 0.74, P = 0.03). These ratio differences between groups grew at the 24 months follow-up visit (2.04 +/- 0.86 vs 1.65 +/- 0.65, P < 0.001). Within the FEP group, there were no significant differences in NLR across the follow-up visits, between genders or diagnosis groups (affective vs nonaffective). NLR values did not correlate with the Positive and Negative Symptoms Scale scores. The group of patients who did not reach remission criteria at the end of the study showed a significant higher NLR than those who remitted (2.1896 +/- 0.85 vs 1.95 +/- 0.87, P = 0.042). A significant correlation between antipsychotic doses and NLR was found at the two-years follow-up visit (r=0.461, P < 0.001). Conclusions Our results highlight the existence of an underlying predisposition of FEP patients to present an increased mean NLR. The use of NLR in clinical practice could be helpful to identify this inflammatory imbalance.
Filiaciones:
Bioque, M:
Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit BCSU, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Barcelona, Dept Med, Barcelona, Spain
Matias-Martins, AC:
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Llorca-Bofi, V:
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Mezquida, G:
Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit BCSU, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Barcelona, Dept Basic Clin Practice, Pharmacol Unit, Barcelona, Spain
Cuesta, MJ:
Hosp Univ Navarra, Dept Psychiat, Navarra, Spain
Navarra Inst Hlth Res IdiSNA, Pamplona, Spain
Vieta, E:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Barcelona, Dept Med, Barcelona, Spain
Hosp Clin Barcelona, Inst Neurosci, Bipolar & Depress Disorders Unit, Barcelona, Spain
Amoretti, S:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Hosp Clin Barcelona, Inst Neurosci, Bipolar & Depress Disorders Unit, Barcelona, Spain
Vall dHebron Res Inst VHIR, Psychiat Genet Unit, Grp Psychiat Mental Hlth & Addict, Barcelona, Spain
Lobo, A:
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Zaragoza, Dept Med & Psychiat, Zaragoza, Spain
Gonzalez-Pinto, A:
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Hosp Univ Araba, Serv Psiquiatria, UPV EHU, Bioaraba, Spain
Moreno, C:
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth, Inst Invest Sanitaria Gregorio Maranon IiSGM, Dept Child & Adolescent Psychiat, Madrid, Spain
Univ Complutense, Sch Med, Madrid, Spain
Roldan, A:
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Psychiat Dept, IIB SANT PAU, Inst Invest Biomed St Pau, Barcelona, Spain
Univ Autonoma Barcelona UAB, Barcelona, Spain
Martinez-Aran, A:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Barcelona, Dept Med, Barcelona, Spain
Hosp Clin Barcelona, Inst Neurosci, Bipolar & Depress Disorders Unit, Barcelona, Spain
Baeza, I:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Barcelona, Dept Med, Barcelona, Spain
Hosp Clin Barcelona, Child & Adolescent Psychiat & Psychol Dept, SGR 881, Barcelona, Spain
Berge, D:
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Hosp Mar Med Res Inst IMIM, Barcelona, Spain
Pompeu Fabra Univ UPF, Barcelona, Spain
Garcia-Rizo, C:
Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit BCSU, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Barcelona, Dept Med, Barcelona, Spain
Herrero, SM:
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Barcelona, Dept Basic Clin Practice, Pharmacol Unit, Barcelona, Spain
Bernardo, M:
Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit BCSU, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Univ Barcelona, Dept Med, Barcelona, Spain
|